PDCD1 and hereditary sensory and autonomic neuropathy: This difference in incidence may be due, in part, to the greater frequency of computed tomography (CT) in our routine clinical practice, which may have led to earlier detection, and to the inclusion of patients at potential risk for CIP who received PD‐1 inhibitors outside of clinical trials.